Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The "STORE" Study: Journal of acquired immune deficiency syndromes (1999)

A. Gori, A. Antinori, A. Vergori, M.V. Cossu, B. Menzaghi, G. Sterrantino, S. Rusconi, A.M. Cattelan, F. Castelli, N. Gianotti, G. Orofino, D. Ripamonti, S. Savinelli, E. Manzillo, T.A. Santantonio, B.M. Celesia, R. Cauda, R. Maserati, A. dʼArminio Monforte, C. StingoneS. Bonora, A. Uglietti, R. Termini, F. Rucci, D. Mancusi

Research output: Contribution to journalArticlepeer-review

Abstract

OBJECTIVE: This study investigates the effectiveness and tolerability of switching to a darunavir/cobicistat (DRV/c)-based antiretroviral regimen from a ritonavir-boosted protease inhibitor (PI/r)-based regimen in virologically suppressed HIV-positive patients. DRV trough values were also investigated. SETTING: Prospective, multicenter, single-country, noninterventional cohort study. METHODS: This study included patients on a PI/r-based ART for at least 12 months having plasma HIV-1 RNA
Original languageEnglish
Pages (from-to)290-294
Number of pages5
JournalJ Acquir Immune Defic Syndr
Volume84
Issue number3
DOIs
Publication statusPublished - 2020

Keywords

  • anti human immunodeficiency virus agent
  • cobicistat
  • darunavir
  • Human immunodeficiency virus proteinase inhibitor
  • ritonavir
  • virus RNA
  • adult
  • blood
  • clinical trial
  • drug effect
  • female
  • human
  • Human immunodeficiency virus 1
  • Human immunodeficiency virus infection
  • male
  • middle aged
  • multicenter study
  • prospective study
  • virus load
  • Adult
  • Anti-HIV Agents
  • Cobicistat
  • Darunavir
  • Female
  • HIV Infections
  • HIV Protease Inhibitors
  • HIV Seropositivity
  • HIV-1
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Ritonavir
  • RNA, Viral
  • Viral Load

Fingerprint Dive into the research topics of 'Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The "STORE" Study: Journal of acquired immune deficiency syndromes (1999)'. Together they form a unique fingerprint.

Cite this